sliderimage
sliderimage
About FLH
Trusted care,
healing commitment.

Frontline Hospital is a 200 bedded multispecialty hospital situated at Old Baneshwor, Kathmandu providing world-class medical care at an affordable price. Our goal is to offer the most advanced state-of-the-art globally competitiv...

DETERMINATION
We are determined to provide the best medical infrastructure
DILIGENCE
We will follow the highest standard of professionalism
DHARMA
Principle of duty towards the nation, society, and individuals.
Our Departments
Ent-head & neck surgery
Orthopaedics
General, gi & laparoscopic surgery
Obstetric & gynaecology
Internal medicine & family medicine
Pulmonology
Neurosurgery & neuro medicine
Pediatrics/pediatric pulmonology
Pediatric orthopedics
Cardiology
Cardiothoracic & vascular surgery (ctvs)
Gastroenterology, hepatology and endoscopy
Urology & kidney transplantation
Nephrology
Dermato-venereology & cosmetology
Plastic surgery and reconstruction
Psychiatry and clinical psychology
Neuropsychiatry
Diabetic & endocrinology
Geriatric medicine
Dental & maxillofacial surgery
Emergency medicine and pre-hospital care
Ophthalmology
Hematology
Critical care medicine
Nicu/picu
Anesthesia & pain management
Dietetics/food and nutrition
Radiology & imaging
Laboratory medicine and pathology
Physiotherapy and rehabilitation
Wellness
Ent-head & neck surgery
ENT/HNS ENT (Ear, Nose, and Throat) surgery is a medical specialty that deals with the surgical treatment of conditions related to the ear, nose, and throat. ENT at Frontline Hospital aims to improve the patient's hearing, breathing, and speech, and to relieve pain or discomfort associated with various conditions. Some common procedures performed in ENT surgery include: Hearing Tests (Audiogram, Tympanometry), Hearing Aids, Speech Therapy, Ear Disorders, ENT Procedures and Surgeries, Endoscopic Sinus Surgeries, Other Major & Minor ENT Surgeries, Thyroid and Neck Surgery, Head, Neck and Mouth Cancer Surgeries, Microscopic Laryngeal Surgeries (MLS)...
  • ENT-HNS
Board of Directors
Mr. Uttam Bhaukajee
BOD
Mr. Santosh Mani Neupane
BOD
Mr. Nawaraj Pandey
Chairman
Mr. Rabin Dahal
BOD
Mr. Shankar Shrestha
BOD
Messages
Mr. Nawaraj Pandey
Executive Chairman
FRONTLINE is committed to providing evidence-based, team-led healthcare by excellent clinical professionals. Thank you for your interest in FRONTLINE and urge to witness and observe the difference we bring together in the healthcare sector. Wish you all good health!
Dr. Yogesh Neupane
Clinical President
We envision leading urban healthcare by providing compassionate high-quality care for Nepal and South Asia. We will not stop there but pursue excellent clinical outcomes with continuous improvement of clinical practices.
Mr. Krishna Bahadur Nepali
DCOO, FRONTLINE HOSPITAL
At Frontline Hospital, we are focused on building relationships through top-class infrastructure, the latest equipment, and a highly qualified and dedicated team of medical and support professionals. We have aimed at bringing tertiary Medicare at the most affordable rates to all. Thank You.
Our Doctors
99+
Qualified Doctors
100%
Patient Satisfaction
90+
Winning Awards
400 Above
Successful Surgery
Look What Our
Patients Says !
We are determined to provide the best medical infrastructure
Meet Priyanka Tripathi, as she talks about women's health and shares her knowledge.
Priyanka Tripathi Doctor

Frontline Hospital is a 200 bedded multispecialty hospital

FRONTLINE HOSPITAL Hospital
News and Articles
2024-01-03
24 HRS. EMERGENCY SERVICES
The health industry has shifted to value-based care i.e. total care from the traditional pay-for-service model. Frontline assures that all the patient’s health needs are addressed and all issues are solved timely by professional doctors and nurses who provide one-on-one care to patients.
By: Front Line Hospital
2024-01-08
SAGE COVID-19 vaccination guidance

Following its 20-23 March meeting, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) revised the roadmap for prioritizing the use of COVID-19 vaccines, to reflect the impact of Omicron and high population-level immunity due to infection and vaccination. The roadmap continues SAGE’s prioritization of protecting populations at the greatest risk of death and severe disease from SARS-CoV-2 infection and its focus on maintaining resilient health systems. The roadmap newly considers the cost-effectiveness of COVID-19 vaccination for those at lower risk – namely healthy children and adolescents – compared to other health interventions. The roadmap also includes revised recommendations on additional booster doses and the spacing of boosters.

The current COVID-19 vaccines’ reduction of post-COVID conditions is also considered but the evidence on the extent of their impact is inconsistent. “Updated to reflect that much of the population is either vaccinated or previously infected with COVID-19, or both, the revised roadmap reemphasizes the importance of vaccinating those still at-risk of severe disease, mostly older adults and those with underlying conditions, including with additional boosters,” stated SAGE Chair Dr Hanna Nohynek. “Countries should consider their specific context in deciding whether to continue vaccinating low risk groups, like healthy children and adolescents, while not compromising the routine vaccines that are so crucial for the health and well-being of this age group.” The revised roadmap outlines three priority-use groups for COVID-19 vaccination: high, medium, and low. These priority groups are principally based on risk of severe disease and death, and consider vaccine performance, cost-effectiveness, programmatic factors and community acceptance. The high priority group includes older adults; younger adults with significant comorbidities (e.g. diabetes and heart disease); people with immunocompromising conditions (e.g. people living with HIV and transplant recipients), including children aged 6 months and older; pregnant persons; and frontline health workers. For the high priority group, SAGE recommends an additional booster of either 6 or 12 months after the last dose, with the timeframe depending on factors such as age and immunocompromising conditions. All the COVID-19 vaccine recommendations are time-limited, applying for the current epidemiological scenario only, and so the additional booster recommendations should not be seen as for continued annual COVID-19 vaccine boosters. The aim is to serve countries planning for the near- to mid-term. The medium priority group includes healthy adults – usually under the age of 50-60 – without comorbidities and children and adolescents with comorbidities. SAGE recommends primary series and first booster doses for the medium priority group. Although additional boosters are safe for this group, SAGE does not routinely recommend them, given the comparatively low public health returns. The low priority group includes healthy children and adolescents aged 6 months to 17 years. Primary and booster doses are safe and effective in children and adolescents. However, considering the low burden of disease, SAGE urges countries considering vaccination of this age group to base their decisions on contextual factors, such as the disease burden, cost effectiveness, and other health or programmatic priorities and opportunity costs. The public health impact of vaccinating healthy children and adolescents is comparatively much lower than the established benefits of traditional essential vaccines for children – such as the rotavirus, measles, and pneumococcal conjugate vaccines – and of COVID-19 vaccines for high and medium priority groups. Children with immunocompromising conditions and comorbidities do face a higher risk of severe COVID-19, so are included in the high and medium priority groups respectively. Though low overall, the burden of severe COVID-19 in infants under 6 months is still higher than in children aged 6 months to 5 years. Vaccinating pregnant persons – including with an additional dose if more than 6 months have passed since the last dose – protects both them and the fetus, while helping to reduce the likelihood of hospitalization of infants for COVID-19. Countries that already have a policy in place for additional boosters should assess the evolving need based on national disease burden, cost effectiveness and opportunity costs.

By: Roshan Karki
FAQ